Search research articles
Contact Us
Filters
Showing results (61-70 of 92) with videos related to
Page
of 10
Sort By:
Allergy
|
May 29, 2014
Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459
R Pettipher, M G Hunter, C M Perkins, et al.
Haematologica
|
July 18, 2020
Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice
Emily R Finch, Monique A Payton, David A Jenkins, et al.
Pediatric Blood & Cancer
|
December 6, 2021
Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy
Emily R Finch, Laura J Janke, Lie Li, et al.
Journal of Molecular Biology
|
April 1, 1994
Crystallization and preliminary X-ray analysis of Candida albicans phosphomannose isomerase
S Tolley, G Davies, R E Hubbard, et al.
American Journal of Medical Genetics
|
January 23, 2002
No association between CHRNA7 microsatellite markers and attention-deficit hyperactivity disorder
L Kent, E Green, J Holmes, et al.
Human Immunology
|
June 1, 1997
HLA-DQ alleles associate with cutaneous features of onchocerciasis. The Kaduna-London-Manchester Collaboration for Research on Onchocerciasis
M E Murdoch, A Payton, A Abiose, et al.
Nature Structural Biology
|
May 1, 1996
The x-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 angstrom resolution
A Cleasby, A Wonacott, T Skarzynski, et al.
Pediatric Blood & Cancer
|
June 14, 2021
Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models
Laura J Janke, Jieun Kim, Monique A Payton, et al.
Plos One
|
May 7, 2019
Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models
Seth E Karol, Laura J Janke, John C Panetta, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 23, 2011
Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils
Roy Pettipher, Shân L Vinall, Luzheng Xue, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 92) with videos related to
Sort By:
Page
of 10
Allergy
|
May 29, 2014
Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459
R Pettipher, M G Hunter, C M Perkins, et al.
Haematologica
|
July 18, 2020
Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice
Emily R Finch, Monique A Payton, David A Jenkins, et al.
Pediatric Blood & Cancer
|
December 6, 2021
Dasatinib does not exacerbate dexamethasone-induced osteonecrosis in murine models of acute lymphoblastic leukemia therapy
Emily R Finch, Laura J Janke, Lie Li, et al.
Journal of Molecular Biology
|
April 1, 1994
Crystallization and preliminary X-ray analysis of Candida albicans phosphomannose isomerase
S Tolley, G Davies, R E Hubbard, et al.
American Journal of Medical Genetics
|
January 23, 2002
No association between CHRNA7 microsatellite markers and attention-deficit hyperactivity disorder
L Kent, E Green, J Holmes, et al.
Human Immunology
|
June 1, 1997
HLA-DQ alleles associate with cutaneous features of onchocerciasis. The Kaduna-London-Manchester Collaboration for Research on Onchocerciasis
M E Murdoch, A Payton, A Abiose, et al.
Nature Structural Biology
|
May 1, 1996
The x-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 angstrom resolution
A Cleasby, A Wonacott, T Skarzynski, et al.
Pediatric Blood & Cancer
|
June 14, 2021
Effects of zoledronic acid on osteonecrosis and acute lymphoblastic leukemia treatment efficacy in preclinical models
Laura J Janke, Jieun Kim, Monique A Payton, et al.
Plos One
|
May 7, 2019
Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models
Seth E Karol, Laura J Janke, John C Panetta, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 23, 2011
Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils
Roy Pettipher, Shân L Vinall, Luzheng Xue, et al.
Page
of 10